<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37012057</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000799</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000799</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To combine targeted transcriptomic and proteomic data in an unsupervised hierarchical clustering method to stratify patients with childhood-onset SLE (cSLE) into similar biological phenotypes, and study the immunological cellular landscape that characterises the clusters.</AbstractText><AbstractText Label="METHODS">Targeted whole blood gene expression and serum cytokines were determined in patients with cSLE, preselected on disease activity state (at diagnosis, Low Lupus Disease Activity State (LLDAS), flare). Unsupervised hierarchical clustering, agnostic to disease characteristics, was used to identify clusters with distinct biological phenotypes. Disease activity was scored by clinical SELENA-SLEDAI (Safety of Estrogens in Systemic Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index). High-dimensional 40-colour flow cytometry was used to identify immune cell subsets.</AbstractText><AbstractText Label="RESULTS">Three unique clusters were identified, each characterised by a set of differentially expressed genes and cytokines, and by disease activity state: cluster 1 contained primarily patients in LLDAS, cluster 2 contained mainly treatment-na&#xef;ve patients at diagnosis and cluster 3 contained a mixed group of patients, namely in LLDAS, at diagnosis and disease flare. The biological phenotypes did not reflect previous organ system involvement and over time, patients could move from one cluster to another. Healthy controls clustered together in cluster 1. Specific immune cell subsets, including CD11c+ B cells, conventional dendritic cells, plasmablasts and early effector CD4+ T cells, differed between the clusters.</AbstractText><AbstractText Label="CONCLUSION">Using a targeted multiomic approach, we clustered patients into distinct biological phenotypes that are related to disease activity state but not to organ system involvement. This supports a new concept where choice of treatment and tapering strategies are not solely based on clinical phenotype but includes measuring novel biological parameters.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wahadat</LastName><ForeName>Mohamed Javad</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-3961-1274</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Tilburg</LastName><ForeName>Sander J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Yvonne M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Harm</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Helden-Meeuwsen</LastName><ForeName>Cornelia G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langerak</LastName><ForeName>Anton W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruijters</LastName><ForeName>Marike J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mubarak</LastName><ForeName>Amani</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verkaaik</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsikis</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Versnel</LastName><ForeName>Marjan A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0245-5386</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamphuis</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1964-352X</Identifier><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands s.kamphuis@erasmusmc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095028" MajorTopicYN="N">Multiomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Disease Activity</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37012057</ArticleId><ArticleId IdType="pmc">PMC10083882</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000799</ArticleId><ArticleId IdType="pii">10/1/e000799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smith EMD, Lythgoe H, Midgley A, et al. . Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol 2019;209:108274. 10.1016/j.clim.2019.108274</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.108274</ArticleId><ArticleId IdType="pubmed">31678365</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot N, Shaikhani D, Teng YKO, et al. . Long-Term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2019;71:290&#x2013;301. 10.1002/art.40697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40697</ArticleId><ArticleId IdType="pmc">PMC6590133</ArticleId><ArticleId IdType="pubmed">30152151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538&#x2013;46. 10.1038/nrrheum.2010.121</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.121</ArticleId><ArticleId IdType="pubmed">20683438</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot N, Kardolus A, Bijl M, et al. . Effects of childhood-onset systemic lupus erythematosus on academic achievements and employment in adult life. J Rheumatol 2021;48:915&#x2013;23. 10.3899/jrheum.191004</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.191004</ArticleId><ArticleId IdType="pubmed">32739896</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau R, Hong S, Cantarel B, et al. . Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016;165:1548&#x2013;50. 10.1016/j.cell.2016.05.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.057</ArticleId><ArticleId IdType="pubmed">27259156</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson GA, Peng J, D&#xf6;nnes P, et al. . Disease-Associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatol 2020;2:e485&#x2013;96. 10.1016/S2665-9913(20)30168-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30168-5</ArticleId><ArticleId IdType="pmc">PMC7425802</ArticleId><ArticleId IdType="pubmed">32818204</ArticleId></ArticleIdList></Reference><Reference><Citation>Panousis NI, Bertsias GK, Ongen H, et al. . Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann Rheum Dis 2019;78:1079&#x2013;89. 10.1136/annrheumdis-2018-214379</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214379</ArticleId><ArticleId IdType="pmc">PMC6691930</ArticleId><ArticleId IdType="pubmed">31167757</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Luu LDW, Jia N, et al. . Multi-platform omics analysis reveals molecular signatures for pathogenesis and activity of systemic lupus erythematosus. Front Immunol 2022;13:833699. 10.3389/fimmu.2022.833699</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.833699</ArticleId><ArticleId IdType="pmc">PMC9063006</ArticleId><ArticleId IdType="pubmed">35514958</ArticleId></ArticleIdList></Reference><Reference><Citation>Trzupek D, Lee M, Hamey F, et al. . Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus. Wellcome Open Res 2021;6:149. 10.12688/wellcomeopenres.16883.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16883.2</ArticleId><ArticleId IdType="pmc">PMC9046903</ArticleId><ArticleId IdType="pubmed">35509371</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehar-Belaid D, Hong S, Marches R, et al. . Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat Immunol 2020;21:1094&#x2013;106. 10.1038/s41590-020-0743-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0743-0</ArticleId><ArticleId IdType="pmc">PMC7442743</ArticleId><ArticleId IdType="pubmed">32747814</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthridge JM, Lu R, Tran L-H, et al. . Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. EClinicalMedicine 2020;20:100291. 10.1016/j.eclinm.2020.100291</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100291</ArticleId><ArticleId IdType="pmc">PMC7058913</ArticleId><ArticleId IdType="pubmed">32154507</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 2019;6:e000270. 10.1136/lupus-2018-000270</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376&#x2013;86. 10.1002/art.39962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, Lit LCW, Tam LS, et al. . Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for TH17-mediated inflammation in auto-immunity. Clin Immunol 2008;127:385&#x2013;93. 10.1016/j.clim.2008.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.01.019</ArticleId><ArticleId IdType="pubmed">18373953</ArticleId></ArticleIdList></Reference><Reference><Citation>Godsell J, Rudloff I, Kandane-Rathnayake R, et al. . Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci Rep 2016;6:34604. 10.1038/srep34604</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep34604</ArticleId><ArticleId IdType="pmc">PMC5052569</ArticleId><ArticleId IdType="pubmed">27708376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruchakorn N, Ngamjanyaporn P, Suangtamai T, et al. . Performance of cytokine models in predicting SLE activity. Arthritis Res Ther 2019;21:287. 10.1186/s13075-019-2029-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-2029-1</ArticleId><ArticleId IdType="pmc">PMC6915901</ArticleId><ArticleId IdType="pubmed">31842967</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918&#x2013;30. 10.1002/art.30613</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahadat MJ, Schonenberg-Meinema D, van Helden-Meeuwsen CG, et al. . Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study. Rheumatology (Oxford) 2022;61:4344&#x2013;54. 10.1093/rheumatology/keac083</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac083</ArticleId><ArticleId IdType="pmc">PMC9629374</ArticleId><ArticleId IdType="pubmed">35143620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller YM, Schrama TJ, Ruijten R, et al. . Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. Nat Commun 2022;13:915. 10.1038/s41467-022-28621-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28621-0</ArticleId><ArticleId IdType="pmc">PMC8854670</ArticleId><ArticleId IdType="pubmed">35177626</ArticleId></ArticleIdList></Reference><Reference><Citation>Park LM, Lannigan J, Jaimes MC. OMIP-069: forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood. Cytometry A 2020;97:1044&#x2013;51. 10.1002/cyto.a.24213</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24213</ArticleId><ArticleId IdType="pmc">PMC8132182</ArticleId><ArticleId IdType="pubmed">32830910</ArticleId></ArticleIdList></Reference><Reference><Citation>Charrad M. NbClust: an R package for determining the relevant number of clusters in a data set. J Stat Softw 2014;61:1&#x2013;36.</Citation></Reference><Reference><Citation>Hennig C. Cluster-wise assessment of cluster stability. Computational Statistics &amp; Data Analysis 2007;52:258&#x2013;71. 10.1016/j.csda.2006.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csda.2006.11.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Fu W, Ranger A, et al. . Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med Genomics 2019;12:4. 10.1186/s12920-018-0468-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-018-0468-1</ArticleId><ArticleId IdType="pmc">PMC6327466</ArticleId><ArticleId IdType="pubmed">30626389</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo YJ, Hwa C, Lee GH, et al. . Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes. Mol Cells 2021;44:433&#x2013;43. 10.14348/molcells.2021.0042</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2021.0042</ArticleId><ArticleId IdType="pmc">PMC8334347</ArticleId><ArticleId IdType="pubmed">34238766</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Adamichou C, Koutsoviti S, et al. . Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: a real-life observational study. Semin Arthritis Rheum 2018;48:467&#x2013;74. 10.1016/j.semarthrit.2018.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2018.02.014</ArticleId><ArticleId IdType="pubmed">29555348</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Gorst SL, Al-Abadi E, et al. . &#x201c; it is good to have a target in mind &#x201d;: qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:5630&#x2013;41. 10.1093/rheumatology/keab173</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab173</ArticleId><ArticleId IdType="pmc">PMC8645274</ArticleId><ArticleId IdType="pubmed">33629109</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant RV, Burger DC, Delo J, et al. . Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016;65:408&#x2013;14. 10.1136/gutjnl-2015-309598</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-309598</ArticleId><ArticleId IdType="pubmed">25986946</ArticleId></ArticleIdList></Reference><Reference><Citation>de Kruif MD, Lemaire LC, Giebelen IA, et al. . Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol 2007;178:1845&#x2013;51. 10.4049/jimmunol.178.3.1845</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.3.1845</ArticleId><ArticleId IdType="pubmed">17237435</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual V, Chaussabel D, Banchereau J. A genomic approach to human autoimmune diseases. Annu Rev Immunol 2010;28:535&#x2013;71. 10.1146/annurev-immunol-030409-101221</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-030409-101221</ArticleId><ArticleId IdType="pmc">PMC2847838</ArticleId><ArticleId IdType="pubmed">20192809</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker-Merok A, Eilertsen G&#xd8;, Nossent JC. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J Rheumatol 2010;37:2039&#x2013;45. 10.3899/jrheum.100180</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100180</ArticleId><ArticleId IdType="pubmed">20682675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubiczkova L, Sedlarikova L, Hajek R, et al. . Tgf-&#x392;-an excellent servant but a bad master. J Transl Med 2012;10:183. 10.1186/1479-5876-10-183</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-10-183</ArticleId><ArticleId IdType="pmc">PMC3494542</ArticleId><ArticleId IdType="pubmed">22943793</ArticleId></ArticleIdList></Reference><Reference><Citation>Smythies LE, Sellers M, Clements RH, et al. . Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005;115:66&#x2013;75. 10.1172/JCI19229</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI19229</ArticleId><ArticleId IdType="pmc">PMC539188</ArticleId><ArticleId IdType="pubmed">15630445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl SM. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 2007;19:55&#x2013;62. 10.1016/j.coi.2006.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2006.11.008</ArticleId><ArticleId IdType="pubmed">17137775</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva E, Yalavarthi S, Berthier CC, et al. . Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187:538&#x2013;52. 10.4049/jimmunol.1100450</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100450</ArticleId><ArticleId IdType="pmc">PMC3119769</ArticleId><ArticleId IdType="pubmed">21613614</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Gunnarsson I, Dorschner J, et al. . High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther 2019;21:107. 10.1186/s13075-019-1878-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId><ArticleId IdType="pmc">PMC6489203</ArticleId><ArticleId IdType="pubmed">31036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahadat MJ, van den Berg L, Timmermans D, et al. . LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med 2021;8:e000571. 10.1136/lupus-2021-000571</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000571</ArticleId><ArticleId IdType="pmc">PMC8719245</ArticleId><ArticleId IdType="pubmed">34969874</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dongen JJM, Lhermitte L, B&#xf6;ttcher S, et al. . EuroFlow antibody panels for standardized N-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908&#x2013;75. 10.1038/leu.2012.120</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2012.120</ArticleId><ArticleId IdType="pmc">PMC3437410</ArticleId><ArticleId IdType="pubmed">22552007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Fu Q, Guo Q, et al. . Lupus-Associated atypical memory B cells are mtorc1-hyperactivated and functionally dysregulated. Ann Rheum Dis 2019;78:1090&#x2013;100. 10.1136/annrheumdis-2019-215039</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215039</ArticleId><ArticleId IdType="pmc">PMC6691860</ArticleId><ArticleId IdType="pubmed">31142473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rincon-Arevalo H, Wiedemann A, Stefanski A-L, et al. . Deep phenotyping of cd11c+ B cells in systemic autoimmunity and controls. Front Immunol 2021;12:635615. 10.3389/fimmu.2021.635615</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.635615</ArticleId><ArticleId IdType="pmc">PMC7994903</ArticleId><ArticleId IdType="pubmed">33777025</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SA, Nowatzky J, Jim&#xe9;nez-Branda S, et al. . Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells. Exp Mol Pathol 2013;95:121&#x2013;3. 10.1016/j.yexmp.2013.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2013.06.003</ArticleId><ArticleId IdType="pmc">PMC3963522</ArticleId><ArticleId IdType="pubmed">23773850</ArticleId></ArticleIdList></Reference><Reference><Citation>Toro-Dom&#xed;nguez D, Martorell-Marug&#xe1;n J, Martinez-Bueno M, et al. . Scoring personalized molecular portraits identify systemic lupus erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression. Brief Bioinform 2022;23:bbac332. 10.1093/bib/bbac332</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbac332</ArticleId><ArticleId IdType="pmc">PMC9487588</ArticleId><ArticleId IdType="pubmed">35947992</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Tang D, Chen D, et al. . Advances in applying of multi-omics approaches in the research of systemic lupus erythematosus. Int Rev Immunol 2020;39:163&#x2013;73. 10.1080/08830185.2020.1736058</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2020.1736058</ArticleId><ArticleId IdType="pubmed">32138562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>